sample_id	title	geo_accession	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1.1	characteristics_ch1.2	characteristics_ch1.3	characteristics_ch1.4	characteristics_ch1.5	characteristics_ch1.6	characteristics_ch1.7	characteristics_ch1.8	characteristics_ch1.9	characteristics_ch1.10	characteristics_ch1.11	characteristics_ch1.12	characteristics_ch1.13	characteristics_ch1.14	characteristics_ch1.15	treatment_protocol_ch1	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	description	description.1	data_processing	platform_id	contact_name	contact_email	contact_phone	contact_laboratory	contact_department	contact_institute	contact_address	contact_city	contact_zip/postal_code	contact_country	supplementary_file	data_row_count	relation	relation.1	relation.2	age:ch1	bmngrd:ch1	er_status:ch1	er:ch1	her2 fish:ch1	her2 ihc:ch1	her2 status:ch1	histology:ch1	nbefore:ch1	pcr_vs_rd:ch1	pr_status:ch1	race:ch1	tbefore:ch1	tissue:ch1	treatment code:ch1	treatments comments:ch1
GSM505327	BR_FNA_M157	GSM505327	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 157, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 57	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol (80mg/m2 q wk), FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505327/suppl/GSM505327_19893_AB01778470_17038.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	57	2	P	90	1.95	2	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	98-240 Taxol (80mg/m2 q wk), FAC x4
GSM505328	BR_FNA_M196	GSM505328	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 196, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 69	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IMC/IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505328/suppl/GSM505328_19893_AB01778504_17045.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	69	2	P	90	1.95	0	N	IMC/IDC	1	RD	P	asian	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC
GSM505329	BR_FNA_M176	GSM505329	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 176, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 77	race: mixed	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 10	her2 status: P	her2 ihc: 2	her2 fish: 3.6	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x1	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505329/suppl/GSM505329_19893_AB01778510_17030.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	77	2	P	10	3.6	2	P	IDC	1	RD	N	mixed	4	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x1
GSM505330	BR_FNA_M214	GSM505330	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 214, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 80	her2 status: N	her2 ihc: NA	her2 fish: 1.15	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly x 12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505330/suppl/GSM505330_19893_AB01779182_17047.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	54	2	P	80	1.15	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 weekly x 12, FAC x4
GSM505331	BR_FNA_M113	GSM505331	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 113, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 75	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q wk (80mg/m2) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505331/suppl/GSM505331_19893_AB01779189_17018.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	75	3	N	0	1.95	0	N	IDC	0	RD	N	black	2	breast cancer cells	TFAC	98-240: Taxol q wk (80mg/m2) x12, FAC x4
GSM505333	BR_FNA_M154	GSM505333	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 154, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 29	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC/IBC	treatment code: Tonly	treatments comments: Taxol 80 mg/m2 weekly off study for PD	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505333/suppl/GSM505333_19893_AB01860198_17037.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	29	3	N	0	1.95	0	N	IDC/IBC	2	RD	N	white	4	breast cancer cells	Tonly	Taxol 80 mg/m2 weekly off study for PD
GSM505334	BR_FNA_M165	GSM505334	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 165, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: black	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 225 mg/m2 x4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505334/suppl/GSM505334_19893_AB01860313_17041.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	50	2	P	90	1.95	0	N	IDC/DCIS	1	RD	N	black	2	breast cancer cells	TFAC	Taxol 225 mg/m2 x4, FAC x4
GSM505335	BR_FNA_M212	GSM505335	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 212, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: asian	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 20	histology: IDC	treatment code: TFAC	treatments comments: Taxol 225 x 4, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505335/suppl/GSM505335_19893_AB01913188_17049.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	42	3	N	0	20	NA	P	IDC	1	pCR	N	asian	2	breast cancer cells	TFAC	Taxol 225 x 4, FEC x 4
GSM505336	BR_FNA_M153	GSM505336	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 153, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 61	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: P	tbefore: 1	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol (150 mg q weekly) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505336/suppl/GSM505336_19893_AB01913261_17092.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	61	3	N	0	1.95	0	N	IDC	1	pCR	P	white	1	breast cancer cells	TFAC	98-240 Taxol (150 mg q weekly) x12, FAC x4
GSM505337	BR_FNA_M220	GSM505337	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 220, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 70	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly x 11, FACx4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505337/suppl/GSM505337_19893_AB01913300_16991.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	38	3	P	70	1.95	0	N	IDC	1	RD	N	white	3	breast cancer cells	TFAC	Taxol 80 weekly x 11, FACx4
GSM505338	BR_FNA_M228	GSM505338	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 228, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: black	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 80	her2 status: N	her2 ihc: 0	her2 fish: 0.81	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100 weekly X 12, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505338/suppl/GSM505338_19893_AB01923090_16992.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	53	2	P	80	0.81	0	N	IDC	1	RD	N	black	4	breast cancer cells	TFAC	Taxol 100 weekly X 12, FAC X 6
GSM505339	BR_FNA_M177	GSM505339	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 177, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: black	er_status: P	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 0	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505339/suppl/GSM505339_19893_AB01943851_17042.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	42	3	P	80	1.95	1	N	IDC	0	pCR	N	black	3	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x4
GSM505340	BR_FNA_M186	GSM505340	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 186, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 7	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505340/suppl/GSM505340_19893_AB01983305_17031.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	54	3	N	0	7	3	P	IDC	0	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x4
GSM505341	BR_FNA_M161	GSM505341	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 161, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 6	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol (100mg/m2 weekly) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505341/suppl/GSM505341_19893_AB01983441_17040.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	44	3	N	0	6	3	P	IDC/DCIS	1	pCR	P	white	2	breast cancer cells	TFAC	Taxol (100mg/m2 weekly) x12, FAC x4
GSM505342	BR_FNA_M159	GSM505342	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 159, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: asian	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 5.5	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol (225mg/m2 q 3 wk), FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505342/suppl/GSM505342_19893_AB01983443_17022.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	59	3	N	0	5.5	NA	P	IDC	0	pCR	N	asian	2	breast cancer cells	TFAC	98-240 Taxol (225mg/m2 q 3 wk), FAC x4
GSM505343	BR_FNA_M130	GSM505343	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 130, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 66	race: asian	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol qwk (150mg/m2) x12, FACx4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505343/suppl/GSM505343_19893_AB01983478_17035.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	66	3	N	0	1.95	0	N	IDC	1	RD	P	asian	2	breast cancer cells	TFAC	98-240: Taxol qwk (150mg/m2) x12, FACx4
GSM505344	BR_FNA_M180	GSM505344	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 180, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12 FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505344/suppl/GSM505344_19893_AB01983865_17043.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	44	3	N	0	1.95	1	N	IDC/DCIS	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12 FAC x4
GSM505345	BR_FNA_M121	GSM505345	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 121, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q wk (80mg/m2) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505345/suppl/GSM505345_19893_AB01983888_17050.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	65	3	N	0	1.95	0	N	IDC	0	RD	N	white	1	breast cancer cells	TFAC	98-240: Taxol q wk (80mg/m2) x12, FAC x4
GSM505346	BR_FNA_M155	GSM505346	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 155, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 0	her2 fish: 1.2	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol (225 mg q 3 wk) x 4, FAX x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505346/suppl/GSM505346_19893_AB01983892_17029.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	62	3	P	80	1.2	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	98-240 Taxol (225 mg q 3 wk) x 4, FAX x4
GSM505347	BR_FNA_M128	GSM505347	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 128, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: ILC/IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q wk (80g/m2) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505347/suppl/GSM505347_19893_AB01983905_17019.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	67	2	P	90	1.95	1	N	ILC/IDC	0	RD	P	white	2	breast cancer cells	TFAC	98-240: Taxol q wk (80g/m2) x12, FAC x4
GSM505348	BR_FNA_M227	GSM505348	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 227, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 30	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100 weekly X 12, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505348/suppl/GSM505348_19893_AB01988136_17034.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	38	3	P	30	1.95	1	N	IDC	1	RD	P	white	3	breast cancer cells	TFAC	Taxol 100 weekly X 12, FAC X 6
GSM505349	BR_FNA_M116	GSM505349	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 116, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 10.7	histology: IDC/IBC	treatment code: TFAC	treatments comments: Taxol q wk (80mg/m2) x 12, No FAC!	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505349/suppl/GSM505349_19893_AB01988400_17051.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	49	3	N	0	10.7	NA	P	IDC/IBC	2	pCR	N	hispanic	4	breast cancer cells	TFAC	Taxol q wk (80mg/m2) x 12, No FAC!
GSM505350	BR_FNA_M156	GSM505350	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 156, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 2	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol (225 mg/m2) x4, FAX x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505350/suppl/GSM505350_19893_AB01988622_17021.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	67	2	N	0	1.95	0	N	IDC	2	RD	N	white	2	breast cancer cells	TFAC	98-240 Taxol (225 mg/m2) x4, FAX x4
GSM505351	BR_FNA_M111	GSM505351	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 111, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q wk (150mg/m2) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505351/suppl/GSM505351_19893_AB01988634_17017.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	50	3	N	0	1.95	1	N	IDC	1	pCR	N	white	3	breast cancer cells	TFAC	98-240: Taxol q wk (150mg/m2) x12, FAC x4
GSM505352	BR_FNA_M201	GSM505352	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 201, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 75	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80mg/m2 weekly x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505352/suppl/GSM505352_19893_AB01988641_17024.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	75	2	P	90	1.95	0	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol 80mg/m2 weekly x 12, FAC x 4
GSM505353	BR_FNA_M188	GSM505353	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 188, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 68	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 1	er: 100	her2 status: N	her2 ihc: NA	her2 fish: 1.21	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505353/suppl/GSM505353_19893_AB01988665_17044.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	68	1	P	100	1.21	NA	N	IDC	1	RD	P	black	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x4
GSM505354	BR_FNA_M158	GSM505354	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 158, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 2	bmngrd: 2	er: 50	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100mg/2 q wk x 12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505354/suppl/GSM505354_19893_AB01988706_17039.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	38	2	P	50	1.95	1	N	IDC	2	RD	P	asian	2	breast cancer cells	TFAC	Taxol 100mg/2 q wk x 12, FAC x4
GSM505355	BR_FNA_M226	GSM505355	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 226, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 31	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 40	her2 status: N	her2 ihc: 1	her2 fish: 0.98	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly X 12, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505355/suppl/GSM505355_19893_AB01988709_17027.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	31	2	P	40	0.98	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 weekly X 12, FAC X 6
GSM505356	BR_FNA_M199	GSM505356	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 199, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 1.09	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100 g/m2 weekly x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505356/suppl/GSM505356_19893_AB01988711_17032.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	3	N	0	1.09	3	P	IDC	1	pCR	N	black	2	breast cancer cells	TFAC	Taxol 100 g/m2 weekly x 12, FAC x 4
GSM505357	BR_FNA_M215	GSM505357	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 215, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.7	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly x 12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505357/suppl/GSM505357_19893_AB01988712_17033.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	44	3	N	0	1.7	2	N	IDC	1	pCR	N	black	2	breast cancer cells	TFAC	Taxol 80 weekly x 12, FAC x4
GSM505358	BR_FNA_M136	GSM505358	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 136, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: P	tbefore: 1	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol 225mg/m2 x 4, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505358/suppl/GSM505358_19893_AB01988722_17036.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	38	3	N	0	1.95	0	N	IDC	0	pCR	P	hispanic	1	breast cancer cells	TFAC	98-240 Taxol 225mg/m2 x 4, FAC x 4
GSM505359	BR_FNA_M206	GSM505359	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 206, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80mg/m2 weekly x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505359/suppl/GSM505359_19893_AB01988742_17046.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	48	3	N	0	1.95	0	N	IDC	0	pCR	N	white	2	breast cancer cells	TFAC	Taxol 80mg/m2 weekly x 12, FAC x 4
GSM505360	BR_FNA_M211	GSM505360	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 211, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80mg/m2 weekly x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505360/suppl/GSM505360_19893_AB01988743_17025.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	52	3	N	0	1.95	0	N	IDC	2	pCR	N	white	3	breast cancer cells	TFAC	Taxol 80mg/m2 weekly x 12, FAC x 4
GSM505361	BR_FNA_M217	GSM505361	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 217, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 50	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly x 12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505361/suppl/GSM505361_19893_AB01988746_17026.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	52	2	P	50	1.95	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 weekly x 12, FAC x4
GSM505362	BR_FNA_M135	GSM505362	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 135, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 0	bmngrd: 3	er: 95	her2 status: P	her2 ihc: 2	her2 fish: 6.1	histology: ILC/IDC	treatment code: TFAC	treatments comments: 98-240 Taxol 80mg/m2 x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505362/suppl/GSM505362_19893_AB01988783_16990.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	51	3	P	95	6.1	2	P	ILC/IDC	0	RD	N	white	3	breast cancer cells	TFAC	98-240 Taxol 80mg/m2 x 12, FAC x 4
GSM505363	BR_FNA_M216	GSM505363	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 216, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 95	her2 status: N	her2 ihc: NA	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 weekly x12 , FAC x 6	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505363/suppl/GSM505363_19893_AB02014530_17059.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	59	2	P	95	NA	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 weekly x12 , FAC x 6
GSM505364	BR_FNA_M139	GSM505364	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 139, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 85	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240 Taxol 225mg/m2 x 4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505364/suppl/GSM505364_19893_AB02014587_17020.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	51	2	P	85	1.95	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	98-240 Taxol 225mg/m2 x 4, FAC x4
GSM505365	BR_FNA_M117	GSM505365	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 117, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 34	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 1	bmngrd: 2	er: 75	her2 status: N	her2 ihc: 2	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q 3wk (225mg/m2) x4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505365/suppl/GSM505365_20537_AB01913201_17055.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	34	2	P	75	1.95	2	N	IDC	1	RD	P	white	4	breast cancer cells	TFAC	98-240: Taxol q 3wk (225mg/m2) x4, FAC x4
GSM505366	BR_FNA_M106	GSM505366	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 106, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 57	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q3 wk (225mg/m2) x4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505366/suppl/GSM505366_20537_AB01913244_17054.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	57	2	P	100	1.95	1	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	98-240: Taxol q3 wk (225mg/m2) x4, FAC x4
GSM505367	BR_FNA_M108	GSM505367	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 108, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 3	er: 90	her2 status: P	her2 ihc: 3	her2 fish: 4.8	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q wk (150mg/m2) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505367/suppl/GSM505367_20537_AB01983919_17056.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	39	3	P	90	4.8	3	P	IDC	0	RD	P	white	4	breast cancer cells	TFAC	98-240: Taxol q wk (150mg/m2) x12, FAC x4
GSM505368	BR_FNA_M123	GSM505368	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 123, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 1	er: 95	her2 status: N	her2 ihc: 1	her2 fish: 1.95	histology: ILC/IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q 3wk (225mg/m2) x4, Fac x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505368/suppl/GSM505368_20558_AB01711719_17202.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	52	1	P	95	1.95	1	N	ILC/IDC	1	pCR	N	white	3	breast cancer cells	TFAC	98-240: Taxol q 3wk (225mg/m2) x4, Fac x4
GSM505369	BR_FNA_M126	GSM505369	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 126, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: white	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol q3wk (225mg/m2) x 4, NO FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505369/suppl/GSM505369_20558_AB01712163_17203.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	59	3	N	0	1.95	2	N	IDC	0	RD	P	white	4	breast cancer cells	TFAC	Taxol q3wk (225mg/m2) x 4, NO FAC
GSM505370	BR_FNA_M205	GSM505370	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 205, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 35	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80mg/m2 weekly x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505370/suppl/GSM505370_20558_AB01724707_17204.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	35	3	N	0	1.95	0	N	IDC	1	pCR	N	white	1	breast cancer cells	TFAC	Taxol 80mg/m2 weekly x 12, FAC x 4
GSM505371	BR_FNA_M182	GSM505371	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 182, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly / FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505371/suppl/GSM505371_20979_AB01913192_16985.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	2	P	100	1.95	0	N	IDC/DCIS	0	RD	P	hispanic	1	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly / FAC x4
GSM505372	BR_FNA_M133	GSM505372	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 133, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: IDC	treatment code: TFAC	treatments comments: 98-240: Taxol q 3wk (225mg/m2) x 4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505372/suppl/GSM505372_20979_AB01913684_16983.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	38	3	N	0	1.95	0	N	IDC	0	RD	N	hispanic	2	breast cancer cells	TFAC	98-240: Taxol q 3wk (225mg/m2) x 4, FAC x4
GSM505373	BR_FNA_M179	GSM505373	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 179, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 5	her2 status: P	her2 ihc: 2	her2 fish: 4.8	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505373/suppl/GSM505373_20979_AB01943782_16982.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	54	3	N	5	4.8	2	P	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x4
GSM505374	BR_FNA_M189	GSM505374	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 189, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 1	her2 fish: 1.12	histology: IMC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505374/suppl/GSM505374_20979_AB01988666_16986.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	47	3	P	80	1.12	1	N	IMC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FAC x4
GSM505375	BR_FNA_M181	GSM505375	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 181, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 75	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 2	er: 20	her2 status: N	her2 ihc: 0	her2 fish: 1.95	histology: ILC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 weekly x12, FACx 3	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505375/suppl/GSM505375_20979_AB01988749_16984.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	75	2	P	20	1.95	0	N	ILC	1	RD	P	white	3	breast cancer cells	TFAC	Taxol 80 mg/m2 weekly x12, FACx 3
GSM505376	BR_FNA_M230	GSM505376	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 230, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.26	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2.q weekly x 12, FEC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505376/suppl/GSM505376_23678_AB01233000_24649.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	58	3	N	0	4.26	3	P	IDC	2	RD	N	white	4	breast cancer cells	TFAC	Taxol 80 mg/m2.q weekly x 12, FEC X 4
GSM505377	BR_FNA_M230R1	GSM505377	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 230, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.26	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2.q weekly x 12, FEC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505377/suppl/GSM505377_23678_AB01233000_26147.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	58	3	N	0	4.26	3	P	IDC	2	RD	N	white	4	breast cancer cells	TFAC	Taxol 80 mg/m2.q weekly x 12, FEC X 4
GSM505378	BR_FNA_M236	GSM505378	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 236, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1	histology: IDC	treatment code: TFAC	treatments comments: 00-005:Taxol weekly x 12,FAC X 5	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505378/suppl/GSM505378_23678_AB01233040_24639.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	53	2	P	90	1	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	00-005:Taxol weekly x 12,FAC X 5
GSM505379	BR_FNA_M236R1	GSM505379	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 236, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1	histology: IDC	treatment code: TFAC	treatments comments: 00-005:Taxol weekly x 12,FAC X 5	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505379/suppl/GSM505379_23678_AB01233040_26137.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	2	P	90	1	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	00-005:Taxol weekly x 12,FAC X 5
GSM505380	BR_FNA_M258	GSM505380	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 258, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.8	histology: IDC	treatment code: TH/FAC	treatments comments: Taxol 100mg/m2 x 12Herceptin, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505380/suppl/GSM505380_23678_AB01299744_24641.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	39	3	N	0	4.8	3	P	IDC	1	RD	N	white	4	breast cancer cells	TH/FAC	Taxol 100mg/m2 x 12Herceptin, FAC X 6
GSM505381	BR_FNA_M258R1	GSM505381	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 258, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.8	histology: IDC	treatment code: TH/FAC	treatments comments: Taxol 100mg/m2 x 12Herceptin, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505381/suppl/GSM505381_23678_AB01299744_26139.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	39	3	N	0	4.8	3	P	IDC	1	RD	N	white	4	breast cancer cells	TH/FAC	Taxol 100mg/m2 x 12Herceptin, FAC X 6
GSM505382	BR_FNA_M246	GSM505382	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 246, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 70	her2 status: N	her2 ihc: 0	her2 fish: 1.05	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505382/suppl/GSM505382_23678_AB01299779_24642.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	42	3	P	70	1.05	0	N	IDC/DCIS	1	RD	N	hispanic	1	breast cancer cells	TFAC	Taxol 80mg/m2.q weekly x 12, FAC X 4
GSM505383	BR_FNA_M246R1	GSM505383	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 246, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 70	her2 status: N	her2 ihc: 0	her2 fish: 1.05	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505383/suppl/GSM505383_23678_AB01299779_26140.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	3	P	70	1.05	0	N	IDC/DCIS	1	RD	N	hispanic	1	breast cancer cells	TFAC	Taxol 80mg/m2.q weekly x 12, FAC X 4
GSM505384	BR_FNA_M237	GSM505384	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 237, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 50	her2 status: P	her2 ihc: 3	her2 fish: 9.52	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 99-146:Taxol weeklyx 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505384/suppl/GSM505384_23678_AB01542140_24651.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	51	3	P	50	9.52	3	P	IDC/DCIS	3	RD	N	hispanic	2	breast cancer cells	TFAC	99-146:Taxol weeklyx 12, FAC x 4
GSM505385	BR_FNA_M237R1	GSM505385	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 237, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 50	her2 status: P	her2 ihc: 3	her2 fish: 9.52	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 99-146:Taxol weeklyx 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505385/suppl/GSM505385_23678_AB01542140_26149.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	3	P	50	9.52	3	P	IDC/DCIS	3	RD	N	hispanic	2	breast cancer cells	TFAC	99-146:Taxol weeklyx 12, FAC x 4
GSM505386	BR_FNA_M239	GSM505386	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 239, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 7.55	histology: IDC	treatment code: TFAC	treatments comments: FAC X 4, Taxol weekly x 12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505386/suppl/GSM505386_23678_AB01542151_24650.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	55	3	N	0	7.55	3	P	IDC	0	pCR	N	white	2	breast cancer cells	TFAC	FAC X 4, Taxol weekly x 12
GSM505387	BR_FNA_M239R1	GSM505387	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 239, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 7.55	histology: IDC	treatment code: TFAC	treatments comments: FAC X 4, Taxol weekly x 12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505387/suppl/GSM505387_23678_AB01542151_26148.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	55	3	N	0	7.55	3	P	IDC	0	pCR	N	white	2	breast cancer cells	TFAC	FAC X 4, Taxol weekly x 12
GSM505388	BR_FNA_M264	GSM505388	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 264, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 3	bmngrd: 3	er: 95	her2 status: P	her2 ihc: NA	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12, FAC X 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505388/suppl/GSM505388_23678_AB01542166_24636.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	62	3	P	95	NA	NA	P	IDC	3	RD	P	black	4	breast cancer cells	TFAC	Taxol 80 mg/m2 x12, FAC X 4
GSM505389	BR_FNA_M264R1	GSM505389	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 264, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 3	bmngrd: 3	er: 95	her2 status: P	her2 ihc: NA	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12, FAC X 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505389/suppl/GSM505389_23678_AB01542166_26134.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	62	3	P	95	NA	NA	P	IDC	3	RD	P	black	4	breast cancer cells	TFAC	Taxol 80 mg/m2 x12, FAC X 4
GSM505390	BR_FNA_M238	GSM505390	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 238, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 56	race: asian	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 91	her2 status: P	her2 ihc: 3	her2 fish: 3.64	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 99-146:Taxol weekly x 12, FACX 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505390/suppl/GSM505390_23678_AB01542220_24643.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	56	2	P	91	3.64	3	P	IDC/DCIS	0	pCR	P	asian	2	breast cancer cells	TFAC	99-146:Taxol weekly x 12, FACX 4
GSM505391	BR_FNA_M238R1	GSM505391	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 238, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 56	race: asian	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 91	her2 status: P	her2 ihc: 3	her2 fish: 3.64	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 99-146:Taxol weekly x 12, FACX 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505391/suppl/GSM505391_23678_AB01542220_26141.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	56	2	P	91	3.64	3	P	IDC/DCIS	0	pCR	P	asian	2	breast cancer cells	TFAC	99-146:Taxol weekly x 12, FACX 4
GSM505392	BR_FNA_M280	GSM505392	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 280, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 71	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 95	her2 status: N	her2 ihc: 2	her2 fish: 1.07	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505392/suppl/GSM505392_23678_AB01542230_24645.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	71	3	P	95	1.07	2	N	IDC	3	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505393	BR_FNA_M280R1	GSM505393	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 280, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 71	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 95	her2 status: N	her2 ihc: 2	her2 fish: 1.07	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505393/suppl/GSM505393_23678_AB01542230_26143.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	71	3	P	95	1.07	2	N	IDC	3	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505394	BR_FNA_M245	GSM505394	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 245, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 90	her2 status: P	her2 ihc: 2	her2 fish: 4.5	histology: IDC/DCIS	treatment code: TH/FAC	treatments comments: Taxol 100mg/m2.q weekly x 12, Trastuzumab, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505394/suppl/GSM505394_23678_AB01542241_24647.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	52	3	P	90	4.5	2	P	IDC/DCIS	3	RD	P	white	2	breast cancer cells	TH/FAC	Taxol 100mg/m2.q weekly x 12, Trastuzumab, FAC X 4
GSM505395	BR_FNA_M245R1	GSM505395	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 245, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 90	her2 status: P	her2 ihc: 2	her2 fish: 4.5	histology: IDC/DCIS	treatment code: TH/FAC	treatments comments: Taxol 100mg/m2.q weekly x 12, Trastuzumab, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505395/suppl/GSM505395_23678_AB01542241_26145.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	52	3	P	90	4.5	2	P	IDC/DCIS	3	RD	P	white	2	breast cancer cells	TH/FAC	Taxol 100mg/m2.q weekly x 12, Trastuzumab, FAC X 4
GSM505396	BR_FNA_M247	GSM505396	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 247, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 2	er: 80	her2 status: N	her2 ihc: 0	her2 fish: 1.02	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505396/suppl/GSM505396_23678_AB01562100_24635.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	54	2	P	80	1.02	0	N	IDC/DCIS	0	RD	P	white	3	breast cancer cells	TFAC	Taxol 80mg/m2.q weekly x 12, FAC X 4
GSM505397	BR_FNA_M247R1	GSM505397	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 247, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 2	er: 80	her2 status: N	her2 ihc: 0	her2 fish: 1.02	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505397/suppl/GSM505397_23678_AB01562100_26133.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	54	2	P	80	1.02	0	N	IDC/DCIS	0	RD	P	white	3	breast cancer cells	TFAC	Taxol 80mg/m2.q weekly x 12, FAC X 4
GSM505398	BR_FNA_M266	GSM505398	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 266, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 1	her2 fish: 0.7	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2 x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505398/suppl/GSM505398_23678_AB01562113_24644.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	45	3	P	80	0.7	1	N	IDC/DCIS	3	RD	N	asian	2	breast cancer cells	TFAC	Taxol 80mg/m2 x 12, FAC X 4
GSM505399	BR_FNA_M266R1	GSM505399	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 266, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 1	her2 fish: 0.7	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2 x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505399/suppl/GSM505399_23678_AB01562113_26142.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	3	P	80	0.7	1	N	IDC/DCIS	3	RD	N	asian	2	breast cancer cells	TFAC	Taxol 80mg/m2 x 12, FAC X 4
GSM505400	BR_FNA_M235	GSM505400	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 235, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 2.98	histology: IDC	treatment code: TFAC	treatments comments: 99-146: Taxol 225mg/m2 q.3 week x 4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505400/suppl/GSM505400_23678_AB01562129_24638.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	53	3	N	0	2.98	3	P	IDC	1	RD	N	black	3	breast cancer cells	TFAC	99-146: Taxol 225mg/m2 q.3 week x 4, FAC x4
GSM505401	BR_FNA_M235R1	GSM505401	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 235, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 2.98	histology: IDC	treatment code: TFAC	treatments comments: 99-146: Taxol 225mg/m2 q.3 week x 4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505401/suppl/GSM505401_23678_AB01562129_26136.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	3	N	0	2.98	3	P	IDC	1	RD	N	black	3	breast cancer cells	TFAC	99-146: Taxol 225mg/m2 q.3 week x 4, FAC x4
GSM505402	BR_FNA_M231	GSM505402	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 231, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 95	her2 status: N	her2 ihc: 0	her2 fish: 0.98	histology: IDC	treatment code: TFAC	treatments comments: 00-005:Taxol 100 mg/m2 x10, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505402/suppl/GSM505402_23678_AB01562130_24648.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	52	2	P	95	0.98	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	00-005:Taxol 100 mg/m2 x10, FAC X 6
GSM505403	BR_FNA_M231R1	GSM505403	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 231, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 95	her2 status: N	her2 ihc: 0	her2 fish: 0.98	histology: IDC	treatment code: TFAC	treatments comments: 00-005:Taxol 100 mg/m2 x10, FAC X 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505403/suppl/GSM505403_23678_AB01562130_26146.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	52	2	P	95	0.98	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	00-005:Taxol 100 mg/m2 x10, FAC X 6
GSM505404	BR_FNA_M257	GSM505404	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 257, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 73	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: P	her2 ihc: 3	her2 fish: 7.81	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100 mg/m2 x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505404/suppl/GSM505404_23678_AB01562152_24646.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	73	2	P	90	7.81	3	P	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 100 mg/m2 x 12, FAC X 4
GSM505405	BR_FNA_M257R1	GSM505405	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 257, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 73	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: P	her2 ihc: 3	her2 fish: 7.81	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100 mg/m2 x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505405/suppl/GSM505405_23678_AB01562152_26144.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	73	2	P	90	7.81	3	P	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 100 mg/m2 x 12, FAC X 4
GSM505406	BR_FNA_M256	GSM505406	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 256, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 79	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 1.19	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100mg/m2.q.weekly x 12,	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505406/suppl/GSM505406_23678_AB01562153_24637.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	79	3	P	90	1.19	2	N	IDC	3	RD	P	white	2	breast cancer cells	TFAC	Taxol 100mg/m2.q.weekly x 12,
GSM505407	BR_FNA_M256R1	GSM505407	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 256, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 79	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 1.19	histology: IDC	treatment code: TFAC	treatments comments: Taxol 100mg/m2.q.weekly x 12,	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505407/suppl/GSM505407_23678_AB01562153_26135.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	79	3	P	90	1.19	2	N	IDC	3	RD	P	white	2	breast cancer cells	TFAC	Taxol 100mg/m2.q.weekly x 12,
GSM505408	BR_FNA_M270	GSM505408	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 270, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 0	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 0.69	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505408/suppl/GSM505408_23678_AB01562218_24640.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	67	3	P	90	0.69	0	N	IDC	0	RD	N	white	4	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505409	BR_FNA_M270R1	GSM505409	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 270, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 0	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 0.69	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505409/suppl/GSM505409_23678_AB01562218_26138.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	67	3	P	90	0.69	0	N	IDC	0	RD	N	white	4	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505410	BR_FNA_M259	GSM505410	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 259, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 20	her2 status: P	her2 ihc: 3	her2 fish: 1.2	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505410/suppl/GSM505410_24817_AB02260707_26166.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	39	3	P	20	1.2	3	P	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12, FAC X 4
GSM505411	BR_FNA_M301	GSM505411	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 301, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 5	her2 status: N	her2 ihc: 0	her2 fish: 0.986	histology: IDC/anaplastic	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FAC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505411/suppl/GSM505411_24817_AB02260970_26172.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	46	3	N	5	0.986	0	N	IDC/anaplastic	1	pCR	N	black	3	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FAC X4
GSM505412	BR_FNA_M234	GSM505412	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 234, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 2	er: 85	her2 status: N	her2 ihc: 1	her2 fish: 1.02	histology: IDC/ILC/LCIS	treatment code: TFAC	treatments comments: 00-005:Taxol 100mg/m2.q weekly x10, FAC X 4.	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505412/suppl/GSM505412_24817_AB02261485_26161.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	58	2	P	85	1.02	1	N	IDC/ILC/LCIS	1	RD	N	white	3	breast cancer cells	TFAC	00-005:Taxol 100mg/m2.q weekly x10, FAC X 4.
GSM505413	BR_FNA_M310	GSM505413	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 310, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 0	her2 status: N	her2 ihc: NA	her2 fish: 1.07	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FAC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505413/suppl/GSM505413_24817_AB02261505_26168.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	51	2	N	0	1.07	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FAC X4
GSM505414	BR_FNA_M251	GSM505414	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 251, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 79	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 100	her2 status: P	her2 ihc: 3	her2 fish: 5.23	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2. q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505414/suppl/GSM505414_24817_AB02261508_26167.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	79	3	P	100	5.23	3	P	IDC/DCIS	1	RD	P	white	3	breast cancer cells	TFAC	Taxol 80mg/m2. q weekly x 12, FAC X 4
GSM505415	BR_FNA_M260	GSM505415	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 260, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 50	her2 status: N	her2 ihc: 0	histology: IDC/ILC	treatment code: TFAC	treatments comments: Taxol 100mg/m2 x 12, FAC X 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505415/suppl/GSM505415_24817_AB02261512_26160.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	50	3	P	50	NA	0	N	IDC/ILC	1	RD	P	white	3	breast cancer cells	TFAC	Taxol 100mg/m2 x 12, FAC X 4
GSM505416	BR_FNA_M255	GSM505416	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 255, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 0.98	histology: IDC/ILC/DCIS	treatment code: TFAC	treatments comments: Taxol 80mg/m2.q.weekly x12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505416/suppl/GSM505416_24817_AB02262603_26162.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	48	2	N	0	0.98	1	N	IDC/ILC/DCIS	3	RD	N	white	2	breast cancer cells	TFAC	Taxol 80mg/m2.q.weekly x12, FAC X 4
GSM505417	BR_FNA_M286	GSM505417	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 286, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 2	her2 fish: 2.71	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505417/suppl/GSM505417_24817_AB02262619_26171.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	51	3	N	0	2.71	2	P	IDC	1	RD	N	white	3	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505418	BR_FNA_M287	GSM505418	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 287, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 9.01	histology: IDC	treatment code: TFAC	treatments comments: FEC X3, Taxol 80 mg/m2 x12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505418/suppl/GSM505418_24817_AB02262650_26174.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	55	3	N	0	9.01	NA	P	IDC	2	RD	N	white	4	breast cancer cells	TFAC	FEC X3, Taxol 80 mg/m2 x12
GSM505419	BR_FNA_M309	GSM505419	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 309, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 8.77	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505419/suppl/GSM505419_24817_AB02263363_26173.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	62	3	N	0	8.77	NA	P	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505420	BR_FNA_M304	GSM505420	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 304, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 ihc: NA	her2 fish: 1.1	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505420/suppl/GSM505420_24817_AB02263375_26169.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	2	P	90	1.1	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505421	BR_FNA_M233	GSM505421	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 233, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 60	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 00-005: Taxol 80 mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505421/suppl/GSM505421_24817_AB02263389_26164.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	60	3	N	0	1	0	N	IDC/DCIS	3	RD	N	white	4	breast cancer cells	TFAC	00-005: Taxol 80 mg/m2.q weekly x 12, FAC X 4
GSM505422	BR_FNA_M297	GSM505422	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 297, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: black	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 2	er: 90	her2 status: N	her2 ihc: NA	her2 fish: 1.39	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FAC X6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505422/suppl/GSM505422_24817_AB02263395_26170.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	65	2	P	90	1.39	NA	N	IDC	2	RD	N	black	4	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FAC X6
GSM505423	BR_FNA_M295	GSM505423	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 295, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 2	her2 status: N	her2 ihc: 0	her2 fish: 1.55	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FAC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505423/suppl/GSM505423_24817_AB02263399_26158.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE205568	NA	48	3	N	2	1.55	0	N	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FAC X4
GSM505424	BR_FNA_M282	GSM505424	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 282, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	histology: IC/DCIS	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505424/suppl/GSM505424_24817_AB02263400_26163.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	44	2	P	90	NA	0	N	IC/DCIS	1	RD	N	white	1	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505425	BR_FNA_M302	GSM505425	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 302, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: mixed	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 9.09	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505425/suppl/GSM505425_24817_AB02263405_26175.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	50	3	N	0	9.09	NA	P	IDC	3	RD	P	mixed	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505426	BR_FNA_M261	GSM505426	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 261, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 56	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 85	her2 status: N	her2 ihc: NA	her2 fish: 1.01	histology: IDC/DCIS	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12, FEC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505426/suppl/GSM505426_24817_AB02263410_26165.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	56	2	P	85	1.01	NA	N	IDC/DCIS	0	RD	P	white	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12, FEC X 4
GSM505427	BR_FNA_M333	GSM505427	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 333, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1.88	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505427/suppl/GSM505427_28998_AB02077268_34965.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	67	3	P	100	1.88	ND	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505428	BR_FNA_M402	GSM505428	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 402, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 5	her2 status: N	her2 ihc: ND	her2 fish: 0.68	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505428/suppl/GSM505428_28998_AB02086473_34898.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	38	3	N	5	0.68	ND	N	IDC	1	pCR	N	white	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505429	BR_FNA_M387	GSM505429	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 387, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 28	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 3	er: 90	her2 status: P	her2 ihc: 3	her2 fish: 5.75	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505429/suppl/GSM505429_28998_AB02086494_34889.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	28	3	P	90	5.75	3	P	IDC	0	RD	P	white	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505430	BR_FNA_M386	GSM505430	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 386, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1.67	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505430/suppl/GSM505430_28998_AB02086509_34967.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	2	P	100	1.67	ND	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505431	BR_FNA_M322	GSM505431	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 322, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 50	her2 status: P	her2 ihc: ND	her2 fish: 2.5	histology: IDC+ILC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505431/suppl/GSM505431_28998_AB02088695_34964.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	65	3	P	50	2.5	ND	P	IDC+ILC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505432	BR_FNA_M375	GSM505432	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 375, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 0.99	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505432/suppl/GSM505432_28998_AB02090183_34891.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	64	3	N	0	0.99	1	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505433	BR_FNA_M330	GSM505433	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 330, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 35	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 3	bmngrd: 2	er: 10	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x ( ), FEC x ( )	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505433/suppl/GSM505433_28998_AB02090231_34822.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	35	2	P	10	NA	0	N	IDC	3	RD	P	white	3	breast cancer cells	TFAC	PACLITAXEL x ( ), FEC x ( )
GSM505434	BR_FNA_M316	GSM505434	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 316, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.59	histology: IDC + DCIS	treatment code: TH/FEC	treatments comments: Taxol/FEC+Herceptin: updated from(PACLITAXEL x 12, FEC x 4)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505434/suppl/GSM505434_28998_AB02090665_34888.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	3	N	0	4.59	3	P	IDC + DCIS	3	pCR	N	white	4	breast cancer cells	TH/FEC	Taxol/FEC+Herceptin: updated from(PACLITAXEL x 12, FEC x 4)
GSM505435	BR_FNA_M331	GSM505435	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 331, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 71	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 2	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 9.26	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505435/suppl/GSM505435_28998_AB02090710_34885.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	71	2	N	0	9.26	3	P	IDC	1	pCR	N	hispanic	1	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505436	BR_FNA_ML20	GSM505436	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- L20, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: black	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 4	nbefore: 1	bmngrd: 3	her2 status: N	her2 ihc: NEG	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505436/suppl/GSM505436_28998_AB02091099_34966.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	48	3	P	NA	NA	NEG	N	IDC	1	pCR	P	black	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505437	BR_FNA_M371R1	GSM505437	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 371, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 6.25	histology: IDC	treatment code: TH/FAC	treatments comments: Taxol/Herceptin+FAC: updated from(PACLITAXEL x 12, FEC x 4)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505437/suppl/GSM505437_28999_AB01374958_33678.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	3	N	0	6.25	3	P	IDC	3	pCR	N	hispanic	4	breast cancer cells	TH/FAC	Taxol/Herceptin+FAC: updated from(PACLITAXEL x 12, FEC x 4)
GSM505438	BR_FNA_M402R1	GSM505438	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 402, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 5	her2 status: N	her2 ihc: ND	her2 fish: 0.68	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505438/suppl/GSM505438_28999_AB01468529_33679.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	38	3	N	5	0.68	ND	N	IDC	1	pCR	N	white	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505439	BR_FNA_M331R1	GSM505439	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 331, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 71	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 2	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 9.26	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505439/suppl/GSM505439_28999_AB01469468_31425.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	71	2	N	0	9.26	3	P	IDC	1	pCR	N	hispanic	1	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505440	BR_FNA_M375R1	GSM505440	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 375, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 0.99	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505440/suppl/GSM505440_28999_AB01469507_34970.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	64	3	N	0	0.99	1	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505441	BR_FNA_M322R1	GSM505441	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 322, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 50	her2 status: P	her2 ihc: ND	her2 fish: 2.5	histology: IDC+ILC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505441/suppl/GSM505441_28999_AB01469529_31431.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	65	3	P	50	2.5	ND	P	IDC+ILC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505442	BR_FNA_M333R1	GSM505442	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 333, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1.88	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505442/suppl/GSM505442_28999_AB01469644_31430.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	67	3	P	100	1.88	ND	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505443	BR_FNA_M387R1	GSM505443	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 387, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 28	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 3	er: 90	her2 status: P	her2 ihc: 3	her2 fish: 5.75	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505443/suppl/GSM505443_28999_AB01469822_33681.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	28	3	P	90	5.75	3	P	IDC	0	RD	P	white	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505444	BR_FNA_M386R1	GSM505444	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 386, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1.67	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505444/suppl/GSM505444_28999_AB01469842_34742.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	2	P	100	1.67	ND	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505445	BR_FNA_M316R1	GSM505445	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 316, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 4.59	histology: IDC + DCIS	treatment code: TH/FEC	treatments comments: Taxol/FEC+Herceptin: updated from(PACLITAXEL x 12, FEC x 4)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505445/suppl/GSM505445_28999_AB01469868_33680.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	3	N	0	4.59	3	P	IDC + DCIS	3	pCR	N	white	4	breast cancer cells	TH/FEC	Taxol/FEC+Herceptin: updated from(PACLITAXEL x 12, FEC x 4)
GSM505446	BR_FNA_M330R1	GSM505446	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 330, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 35	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 3	bmngrd: 2	er: 10	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x ( ), FEC x ( )	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505446/suppl/GSM505446_28999_AB01470296_31432.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	35	2	P	10	NA	0	N	IDC	3	RD	P	white	3	breast cancer cells	TFAC	PACLITAXEL x ( ), FEC x ( )
GSM505447	BR_FNA_M371	GSM505447	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 371, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 6.25	histology: IDC	treatment code: TH/FAC	treatments comments: Taxol/Herceptin+FAC: updated from(PACLITAXEL x 12, FEC x 4)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505447/suppl/GSM505447_29099_AB02088682_34899.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	3	N	0	6.25	3	P	IDC	3	pCR	N	hispanic	4	breast cancer cells	TH/FAC	Taxol/Herceptin+FAC: updated from(PACLITAXEL x 12, FEC x 4)
GSM505448	BR_FNA_M323	GSM505448	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 323, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 2	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 0	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x12 FACx 3	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505448/suppl/GSM505448_29539_AB01723009_35679.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	40	3	P	90	ND	0	N	IDC	2	RD	P	hispanic	1	breast cancer cells	TFAC	PACLITAXEL x12 FACx 3
GSM505449	BR_FNA_M442	GSM505449	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 442, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 41	race: white	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 80	her2 status: N	her2 ihc: 0	her2 fish: 1.08	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505449/suppl/GSM505449_29539_AB01723028_35692.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	41	3	P	80	1.08	0	N	IDC	1	pCR	P	white	3	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505450	BR_FNA_PERU14-16	GSM505450	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-14-16, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: NEG	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: 12 PACLITAXEL +4FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505450/suppl/GSM505450_29539_AB01723030_35657.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	58	3	N	0	ND	NEG	N	IDC	2	RD	N	hispanic	4	breast cancer cells	TFAC	12 PACLITAXEL +4FAC
GSM505451	BR_FNA_M523	GSM505451	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 523, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x (12 ), FAC x (4 )	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505451/suppl/GSM505451_29539_AB01723031_35678.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	100	1	ND	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x (12 ), FAC x (4 )
GSM505452	BR_FNA_M315	GSM505452	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 315, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 36	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	her2 status: N	her2 ihc: ND	her2 fish: 1.02	histology: IDC+ILC	treatment code: TFAC	treatments comments: PACLITAXEL x 7 , FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505452/suppl/GSM505452_29539_AB01723032_35694.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	36	2	P	NA	1.02	ND	N	IDC+ILC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 7 , FAC x 4
GSM505453	BR_FNA_M399	GSM505453	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 399, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: ND	her2 fish: 1	histology: IDC + DCIS	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505453/suppl/GSM505453_29539_AB01723039_35684.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	40	2	P	90	1	ND	N	IDC + DCIS	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505454	BR_FNA_M524	GSM505454	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 524, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 31	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x (12), FAC x ( 4)	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505454/suppl/GSM505454_29539_AB01723040_35686.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	31	3	N	0	NA	0	N	IDC	1	pCR	N	hispanic	2	breast cancer cells	TFAC	PACLITAXEL x (12), FAC x ( 4)
GSM505455	BR_FNA_M353	GSM505455	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 353, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: hispanic	er_status: P	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 2	bmngrd: 3	er: 100	her2 status: N	her2 ihc: NEG	her2 fish: 1.19	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505455/suppl/GSM505455_29539_AB01723041_35689.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	3	P	100	1.19	NEG	N	IDC	2	pCR	N	hispanic	3	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505456	BR_FNA_M534	GSM505456	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 534, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 3	bmngrd: 2	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 1.14	histology: IDC	treatment code: TFAC	treatments comments: FEC x 4 , PACLITAXELx (12 )	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505456/suppl/GSM505456_29539_AB01723043_35685.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	2	P	100	1.14	ND	N	IDC	3	RD	P	white	4	breast cancer cells	TFAC	FEC x 4 , PACLITAXELx (12 )
GSM505457	BR_FNA_M447	GSM505457	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 447, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: black	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 95	her2 status: N	her2 ihc: ND	her2 fish: 1.63	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505457/suppl/GSM505457_29539_AB01723044_35687.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	44	2	P	95	1.63	ND	N	IDC	0	RD	N	black	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505458	BR_FNA_M356	GSM505458	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 356, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 ihc: NEG	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505458/suppl/GSM505458_29539_AB01723056_35693.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	55	2	P	100	NA	NEG	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505459	BR_FNA_M367	GSM505459	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 367, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: NA	histology: IDC + DCIS	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505459/suppl/GSM505459_29539_AB01833495_35688.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	62	3	N	0	NA	NA	N	IDC + DCIS	1	pCR	N	white	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505460	BR_FNA_M120	GSM505460	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 120, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: asian	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.1	histology: IDC	treatment code: TFAC	treatments comments: Taxol q 3wk (225mg/m2) x4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505460/suppl/GSM505460_29539_AB01833504_35681.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	52	3	N	0	1.1	0	N	IDC	0	RD	P	asian	2	breast cancer cells	TFAC	Taxol q 3wk (225mg/m2) x4, FAC x4
GSM505461	BR_FNA_M482	GSM505461	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 482, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 80	her2 status: P	her2 ihc: ND	her2 fish: 9.43	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505461/suppl/GSM505461_29539_AB01833515_35616.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	3	P	80	9.43	ND	P	IDC	3	RD	N	hispanic	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505462	BR_FNA_PERU11	GSM505462	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-11, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 0	her2 status: N	her2 ihc: NEG	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: 12 PACLITAXEL + 4FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505462/suppl/GSM505462_29539_AB01833522_35706.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	50	2	N	0	ND	NEG	N	IDC	1	RD	N	hispanic	4	breast cancer cells	TFAC	12 PACLITAXEL + 4FAC
GSM505463	BR_FNA_M141	GSM505463	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 141, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 70	race: hispanic	er_status: P	pcr_vs_rd: pCR	pr_status: N	tbefore: 0	nbefore: 1	bmngrd: 2	er: 50	her2 status: P	her2 ihc: ND	her2 fish: 10.56	histology: IDC	treatment code: TFAC	treatments comments: FAC, X 4, TAXOL X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505463/suppl/GSM505463_29539_AB01833526_35614.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	70	2	P	50	10.56	ND	P	IDC	1	pCR	N	hispanic	0	breast cancer cells	TFAC	FAC, X 4, TAXOL X 4
GSM505464	BR_FNA_M107	GSM505464	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 107, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: black	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 1.27	histology: IDC+DCIS	treatment code: TFAC	treatments comments: Taxol q wk (150mg/m2) x12, Fac x5	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505464/suppl/GSM505464_29539_AB01833535_35695.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	3	P	90	1.27	2	N	IDC+DCIS	1	RD	N	black	3	breast cancer cells	TFAC	Taxol q wk (150mg/m2) x12, Fac x5
GSM505465	BR_FNA_M343	GSM505465	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 343, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 0.86	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505465/suppl/GSM505465_29539_AB01833542_35683.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	2	P	90	0.86	2	N	IDC	3	RD	P	asian	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505466	BR_FNA_M485	GSM505466	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 485, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 1	her2 status: N	her2 ihc: ND	her2 fish: 1.04	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 11, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505466/suppl/GSM505466_29539_AB01833699_35605.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	3	N	1	1.04	ND	N	IDC	2	pCR	N	white	4	breast cancer cells	TFAC	PACLITAXEL x 11, FAC x 4
GSM505467	BR_FNA_M373	GSM505467	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 373, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 0	her2 status: N	her2 ihc: NEG	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505467/suppl/GSM505467_29539_AB01833716_35658.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	46	2	N	0	NA	NEG	N	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505468	BR_FNA_M463	GSM505468	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 463, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 60	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 0.71	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505468/suppl/GSM505468_29539_AB01833728_35659.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	60	3	P	100	0.71	ND	N	IDC	1	RD	N	hispanic	4	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505469	BR_FNA_M357	GSM505469	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 357, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: ND	her2 fish: 0.95	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505469/suppl/GSM505469_29539_AB01833732_35677.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	52	2	P	100	0.95	ND	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505470	BR_FNA_PERU08	GSM505470	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU08, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: FAC	treatments comments: FAC x 6	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505470/suppl/GSM505470_29539_AB01833733_35649.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	40	NA	N	0	NA	0	N	IDC	1	RD	N	hispanic	3	breast cancer cells	FAC	FAC x 6
GSM505471	BR_FNA_PERU12-14	GSM505471	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-12-14, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 2	bmngrd: 3	er: 95	her2 status: N	her2 ihc: NEG	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: 12 PACLITAXEL + 4FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505471/suppl/GSM505471_29539_AB01833741_35650.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	65	3	P	95	ND	NEG	N	IDC	2	RD	P	hispanic	2	breast cancer cells	TFAC	12 PACLITAXEL + 4FAC
GSM505472	BR_FNA_M384	GSM505472	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 384, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 60	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 2	er: 50	her2 status: N	her2 ihc: ND	her2 fish: 1.05	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505472/suppl/GSM505472_29539_AB01833747_35697.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	60	2	P	50	1.05	ND	N	IDC	0	RD	P	hispanic	3	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505473	BR_FNA_M497	GSM505473	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 497, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 20	her2 status: N	her2 ihc: 1	her2 fish: 1.36	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505473/suppl/GSM505473_29539_AB01833749_35607.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	62	3	P	20	1.36	1	N	IDC	3	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505474	BR_FNA_PERU07	GSM505474	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-7, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 71	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 30	her2 status: N	her2 ihc: 1	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: 12 PACLITAXEL + 4FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505474/suppl/GSM505474_29539_AB01833754_35654.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	71	3	P	30	ND	1	N	IDC	1	RD	N	hispanic	4	breast cancer cells	TFAC	12 PACLITAXEL + 4FAC
GSM505475	BR_FNA_M503	GSM505475	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 503, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 38	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505475/suppl/GSM505475_29539_AB01833756_35615.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	38	3	N	0	NA	0	N	IDC	0	RD	N	white	1	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505476	BR_FNA_M129	GSM505476	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 129, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 61	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.11	histology: IDC+DCIS	treatment code: TFAC	treatments comments: Taxol q 3wk (225mg/m2) x 4, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505476/suppl/GSM505476_29539_AB01833758_35698.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	61	2	N	0	1.11	2	N	IDC+DCIS	0	RD	N	white	2	breast cancer cells	TFAC	Taxol q 3wk (225mg/m2) x 4, FAC x4
GSM505477	BR_FNA_M421	GSM505477	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 421, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 2	er: 70	her2 status: N	her2 ihc: NEG	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505477/suppl/GSM505477_29539_AB01833759_35699.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	48	2	P	70	NA	NEG	N	IDC	1	RD	N	white	3	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505478	BR_FNA_M146	GSM505478	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 146, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol (80 mg q weekly) x12, FAC	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505478/suppl/GSM505478_29539_AB01833769_35700.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	40	3	N	0	NA	0	N	IDC	0	pCR	N	white	1	breast cancer cells	TFAC	Taxol (80 mg q weekly) x12, FAC
GSM505479	BR_FNA_M506	GSM505479	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 506, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 95	her2 status: N	her2 ihc: ND	her2 fish: 1.04	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 8 , FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505479/suppl/GSM505479_29539_AB01833780_35612.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	3	P	95	1.04	ND	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 8 , FEC x 4
GSM505480	BR_FNA_PERU09	GSM505480	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-9, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 1	bmngrd: 2	er: 50	her2 status: N	her2 ihc: NEG	her2 fish: ND	histology: IDC	treatment code: TFAC	treatments comments: 12 pACLITAXEL + 4FAC	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505480/suppl/GSM505480_29539_AB01833820_35655.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	50	ND	NEG	N	IDC	1	RD	P	hispanic	4	breast cancer cells	TFAC	12 pACLITAXEL + 4FAC
GSM505481	BR_FNA_M525	GSM505481	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 525, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 40	her2 status: N	her2 ihc: 1	her2 fish: 0.83	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x (12), FAC x ( 4)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505481/suppl/GSM505481_29539_AB01833821_35682.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	3	P	40	0.83	1	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x (12), FAC x ( 4)
GSM505482	BR_FNA_M145	GSM505482	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 145, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 2	bmngrd: 2	er: 80	her2 status: P	her2 ihc: 3	her2 fish: 3.49	histology: IDC+DCIS	treatment code: TFAC	treatments comments: Taxol (150 mg q weekly) x12, FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505482/suppl/GSM505482_29539_AB01833829_35611.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	2	P	80	3.49	3	P	IDC+DCIS	2	RD	P	hispanic	3	breast cancer cells	TFAC	Taxol (150 mg q weekly) x12, FAC x4
GSM505483	BR_FNA_M469	GSM505483	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 469, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 57	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 2	er: 90	her2 status: N	her2 ihc: ND	her2 fish: 1.08	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505483/suppl/GSM505483_29539_AB01833832_35608.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	57	2	P	90	1.08	ND	N	IDC	3	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 6
GSM505484	BR_FNA_M484	GSM505484	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 484, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	her2 status: N	her2 ihc: NEG	her2 fish: 0.94	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 11, FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505484/suppl/GSM505484_29539_AB01833840_35610.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	55	2	P	NA	0.94	NEG	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 11, FAC x 4
GSM505485	BR_FNA_M341	GSM505485	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 341, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 41	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 80	her2 status: N	her2 ihc: ND	her2 fish: 0.96	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505485/suppl/GSM505485_29539_AB01833841_35702.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	41	2	P	80	0.96	ND	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505486	BR_FNA_M434	GSM505486	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 434, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 40	her2 status: N	her2 ihc: 1	her2 fish: 1.07	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505486/suppl/GSM505486_29539_AB01833876_35613.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	2	P	40	1.07	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFAC	PACLITAXEL x 12, FEC x 4
GSM505487	BR_FNA_M334	GSM505487	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 334, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 63	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 1.05	histology: IDC	treatment code: TFAC	treatments comments: PACLITAXEL x 12, FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505487/suppl/GSM505487_29539_AB01833931_35690.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	63	3	N	0	1.05	1	N	IDC	1	RD	N	white	1	breast cancer cells	TFAC	PACLITAXEL x 12, FAC x 4
GSM505488	BR_FNA_PERU01	GSM505488	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU-1, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 73	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 ihc: NEG	histology: IDC	treatment code: TFAC	treatments comments: 12 PACLITAXEL+ 4 FAC	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_T -- Training	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505488/suppl/GSM505488_29539_AB01833935_35648.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	73	2	P	100	NA	NEG	N	IDC	1	RD	N	hispanic	4	breast cancer cells	TFAC	12 PACLITAXEL+ 4 FAC
GSM505489	BR_FNA_PERU53	GSM505489	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU53, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 35	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: FAC	treatments comments: FAC x 6	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505489/suppl/GSM505489_FL398-PERU53.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	35	NA	N	0	NA	0	N	IDC	1	RD	N	hispanic	3	breast cancer cells	FAC	FAC x 6
GSM505490	BR_FNA_PERU55	GSM505490	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- PERU55, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: FAC	treatments comments: FAC x 6	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505490/suppl/GSM505490_FL412-PERU55.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	NA	N	0	NA	0	N	IDC	1	RD	N	hispanic	4	breast cancer cells	FAC	FAC x 6
GSM505491	BR_FNA_M713	GSM505491	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 713, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: NA	her2 fish: 1.1	histology: IDC	treatment code: FEC	treatments comments: FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505491/suppl/GSM505491_FL454-713.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	50	3	N	0	1.1	NA	N	IDC	1	RD	N	white	1	breast cancer cells	FEC	FEC x 4
GSM505492	BR_FNA_US120	GSM505492	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US120, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	er_status: N	pcr_vs_rd: RD	pr_status: N	nbefore: 2	her2 status: P	her2 ihc: 2+	histology: IDC	treatment code: TXFAC	NA	NA	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505492/suppl/GSM505492_U133A_FL112_US120_10_13_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	52	NA	N	NA	NA	2+	P	IDC	2	RD	N	NA	NA	breast cancer cells	TXFAC	NA
GSM505493	BR_FNA_US123	GSM505493	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US123, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	er_status: N	pcr_vs_rd: RD	pr_status: N	her2 status: N	her2 ihc: NA	treatment code: NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505493/suppl/GSM505493_U133A_FL136_US123_11_14_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	NA	NA	N	NA	NA	NA	N	NA	NA	RD	N	NA	NA	breast cancer cells	NA	NA
GSM505494	BR_FNA_US134	GSM505494	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US134, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	her2 status: P	her2 ihc: NA	her2 fish: 3	histology: IDC	treatment code: TXFAC	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505494/suppl/GSM505494_U133A_FL137_US134_11_14_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	NA	P	NA	3	NA	P	IDC	0	RD	P	NA	3	breast cancer cells	TXFAC	NA
GSM505495	BR_FNA_US031	GSM505495	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US031, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	her2 status: P	her2 ihc: NA	her2 fish: 3	histology: IDC	treatment code: TXFAC	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505495/suppl/GSM505495_U133A_FL15_03_17_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	50	3	N	NA	3	NA	P	IDC	1	RD	N	NA	3	breast cancer cells	TXFAC	NA
GSM505496	BR_FNA_US129	GSM505496	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US129, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 1	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TXFAC	NA	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505496/suppl/GSM505496_U133A_FL151_US129_12_08_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	64	NA	N	NA	NA	0	N	IDC	1	pCR	N	NA	3	breast cancer cells	TXFAC	NA
GSM505497	BR_FNA_US125	GSM505497	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US125, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 41	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 2	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TXFAC	NA	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505497/suppl/GSM505497_U133A_FL161_US125_01_10_06.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	41	NA	N	NA	NA	0	N	IDC	2	RD	N	NA	3	breast cancer cells	TXFAC	NA
GSM505498	BR_FNA_US147	GSM505498	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US147, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	her2 status: N	her2 ihc: 2+	her2 fish: 1.5	histology: IDC	treatment code: TXFAC	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505498/suppl/GSM505498_U133A_FL175_US147_01_13_06_2.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	NA	N	NA	1.5	2+	N	IDC	1	RD	N	NA	3	breast cancer cells	TXFAC	NA
GSM505499	BR_FNA_US002	GSM505499	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US002, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 36	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 2	bmngrd: 3	her2 status: N	her2 ihc: 1+	her2 fish: 1.5	histology: IDC	treatment code: TXFAC	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505499/suppl/GSM505499_U133A_FL32-US2_05_19_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	36	3	N	NA	1.5	1+	N	IDC	2	RD	N	NA	3	breast cancer cells	TXFAC	NA
GSM505500	BR_FNA_M314	GSM505500	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 314, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: NA	her2 fish: 1.06	histology: IDC	treatment code: TFAC	treatments comments: FAC x 3 (no response) Taxol x 8 (no response)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505500/suppl/GSM505500_U133A_FL46-314_07_08_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	3	N	0	1.06	NA	N	IDC	3	RD	N	black	3	breast cancer cells	TFAC	FAC x 3 (no response) Taxol x 8 (no response)
GSM505501	BR_FNA_US092	GSM505501	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US092, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 61	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	her2 status: N	her2 ihc: NA	her2 fish: 1.5	histology: ILC	treatment code: TXFAC	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505501/suppl/GSM505501_U133A_FL78_US92_09_01_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	61	NA	P	NA	1.5	NA	N	ILC	0	RD	P	NA	3	breast cancer cells	TXFAC	NA
GSM505502	BR_FNA_US097	GSM505502	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- US097, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.3	histology: ILC	treatment code: TXFAC	NA	NA	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_Q -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505502/suppl/GSM505502_U133A_FL80_US97_09_01_05.CEL.gz	22283	Reanalyzed by: GSE205568	NA	NA	46	NA	P	NA	1.3	0	N	ILC	0	RD	P	NA	3	breast cancer cells	TXFAC	NA
GSM505503	BR_FNA_M233R1	GSM505503	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 233, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 60	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1	histology: IDC/DCIS	treatment code: TFAC	treatments comments: 00-005: Taxol 80 mg/m2.q weekly x 12, FAC X 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505503/suppl/GSM505503_U133A_ROM233_06_04_04.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	60	3	N	0	1	0	N	IDC/DCIS	3	RD	N	white	4	breast cancer cells	TFAC	00-005: Taxol 80 mg/m2.q weekly x 12, FAC X 4
GSM505504	BR_FNA_M286R1	GSM505504	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 286, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 2	her2 fish: 2.71	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505504/suppl/GSM505504_U133A_ROM286_06_04_04.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	3	N	0	2.71	2	P	IDC	1	RD	N	white	3	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505505	BR_FNA_M302R1	GSM505505	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 302, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: mixed	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 ihc: NA	her2 fish: 9.09	histology: IDC	treatment code: TFAC	treatments comments: Taxol 80 mg/m2 x12 , FEC X4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MDA_R -- Not used	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505505/suppl/GSM505505_U133A_ROM302_06_04_04.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	3	N	0	9.09	NA	P	IDC	3	RD	P	mixed	2	breast cancer cells	TFAC	Taxol 80 mg/m2 x12 , FEC X4
GSM505506	BR_FNA_M195	GSM505506	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 195, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 80	her2 status: N	her2 fish: 1.17	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505506/suppl/GSM505506_FL824-195.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	2	P	80	1.17	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505507	BR_FNA_M232	GSM505507	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 232, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 3	er: 1	her2 status: P	her2 ihc: 3	her2 fish: 8	histology: IDC	treatments comments: Taxol q.3 week x 4 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505507/suppl/GSM505507_FL825-232.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	49	3	N	1	8	3	P	IDC	1	pCR	N	white	1	breast cancer cells	NA	Taxol q.3 week x 4 FAC x 4
GSM505508	BR_FNA_M263	GSM505508	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 263, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 72	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 1	her2 status: N	her2 fish: 1.06	histology: ILC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505508/suppl/GSM505508_FL644-263.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	72	1	P	NA	1.06	NA	N	ILC	1	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505509	BR_FNA_M281	GSM505509	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 281, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 ihc: 0	her2 fish: 1.02	histology: IDC	treatment code: TFEC	treatments comments: Taxol q.3 week x 4 FEC  x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505509/suppl/GSM505509_FL747-281.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	2	P	100	1.02	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFEC	Taxol q.3 week x 4 FEC  x 4
GSM505510	BR_FNA_M283	GSM505510	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 283, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 3	er: 95	her2 status: N	her2 fish: 0.71	histology: IDC	treatment code: TFAC	treatments comments: Taxol  x 12  FAC  x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505510/suppl/GSM505510_FL826-283.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	3	P	95	0.71	NA	N	IDC	1	RD	N	white	4	breast cancer cells	TFAC	Taxol  x 12  FAC  x 4
GSM505511	BR_FNA_M294	GSM505511	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 294, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 2	er: 0	her2 status: P	her2 fish: 8.9	histology: IDC	treatments comments: Taxol x 12 FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505511/suppl/GSM505511_FL573-294.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	2	N	0	8.9	NA	P	IDC	1	pCR	N	white	1	breast cancer cells	NA	Taxol x 12 FAC x 4
GSM505512	BR_FNA_M319	GSM505512	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 319, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 26	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 95	her2 status: N	her2 fish: 0.92	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505512/suppl/GSM505512_FL645-319.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	26	2	P	95	0.92	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505513	BR_FNA_M332	GSM505513	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 332, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 50	her2 status: N	her2 fish: 1.09	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 6 (d/t P.D)   FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505513/suppl/GSM505513_28998_AB02090243_34890.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	42	3	P	50	1.09	NA	N	IDC	1	RD	P	white	3	breast cancer cells	TFAC	Taxol x 6 (d/t P.D)   FAC x 4
GSM505514	BR_FNA_M339	GSM505514	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 339, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 0.99	histology: IDC, medullary features	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505514/suppl/GSM505514_FL494-339.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	44	3	N	0	0.99	0	N	IDC, medullary features	1	RD	N	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505515	BR_FNA_M340	GSM505515	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 340, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 54	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 fish: 0.88	histology: IDC	treatment code: TFAC	treatments comments: FAC x 6 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505515/suppl/GSM505515_FL489-340.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	54	2	P	100	0.88	NA	N	IDC	1	RD	N	hispanic	4	breast cancer cells	TFAC	FAC x 6 Taxol x 12
GSM505516	BR_FNA_M345	GSM505516	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 345, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 1.06	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 9 (P.D)  FAC x 8 (P.D) - No Sx	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505516/suppl/GSM505516_FL490-345.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	39	3	N	0	1.06	0	N	IDC	2	RD	N	black	4	breast cancer cells	TFAC	Taxol x 9 (P.D)  FAC x 8 (P.D) - No Sx
GSM505517	BR_FNA_M355	GSM505517	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 355, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 2	bmngrd: 1	er: 90	her2 status: N	her2 fish: 1.11	histology: ILC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505517/suppl/GSM505517_FL495-355.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	59	1	P	90	1.11	NA	N	ILC	2	RD	P	white	3	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505518	BR_FNA_M360	GSM505518	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 360, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 56	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 0	nbefore: 3	bmngrd: 3	er: 90	her2 status: N	her2 fish: 1.22	histology: ILC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505518/suppl/GSM505518_FL745-360.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	56	3	P	90	1.22	NA	N	ILC	3	RD	P	white	0	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505519	BR_FNA_M363	GSM505519	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 363, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 3	er: 100	her2 status: N	her2 fish: 0.78	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505519/suppl/GSM505519_FL746-363.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	58	3	P	100	0.78	NA	N	IDC	0	RD	P	asian	3	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505520	BR_FNA_M365	GSM505520	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 365, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 42	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 1	er: 90	her2 status: N	her2 fish: 1.02	histology: ILC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505520/suppl/GSM505520_U133A_80_FL_080_FL256-365_04_18_06.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	42	1	P	90	1.02	NA	N	ILC	1	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505521	BR_FNA_M382	GSM505521	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 382, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 0	her2 status: P	her2 fish: 10.36	histology: IDC	treatments comments: Taxol x 12 FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505521/suppl/GSM505521_U133A_80_FL_090_FL266-382_04_27_06.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	55	3	N	0	10.36	NA	P	IDC	3	pCR	N	black	2	breast cancer cells	NA	Taxol x 12 FAC x 4
GSM505522	BR_FNA_M385	GSM505522	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 385, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 1	bmngrd: 2	er: 100	her2 status: P	her2 ihc: 2	her2 fish: 2.67	histology: IDC	treatments comments: FEC x 3 ( d/t N.C)Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505522/suppl/GSM505522_U133A_FL58-385_07_27_05.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	65	2	P	100	2.67	2	P	IDC	1	RD	P	white	1	breast cancer cells	NA	FEC x 3 ( d/t N.C)Taxol x 12
GSM505523	BR_FNA_M396	GSM505523	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 396, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 35	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 2	bmngrd: 1	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1.11	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505523/suppl/GSM505523_FL556-396.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	35	1	P	90	1.11	1	N	IDC	2	RD	N	hispanic	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505524	BR_FNA_M411	GSM505524	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 411, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 70	her2 status: N	her2 ihc: 1	her2 fish: 1	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505524/suppl/GSM505524_FL498-411.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	44	2	P	70	1	1	N	IDC	1	RD	P	asian	2	breast cancer cells	TFAC	Taxol x 12 FAC x 6
GSM505525	BR_FNA_M417	GSM505525	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 417, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 63	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 fish: 1.11	histology: ILC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505525/suppl/GSM505525_FL574-417.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	63	2	P	100	1.11	NA	N	ILC	1	RD	P	hispanic	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505526	BR_FNA_M423	GSM505526	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 423, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 68	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 0	nbefore: 3	bmngrd: 2	er: 10	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505526/suppl/GSM505526_U133A_80_FL_082_FL258-423_04_18_06.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	68	2	P	10	NA	0	N	IDC	3	RD	P	black	0	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505527	BR_FNA_M425	GSM505527	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 425, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 60	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 1	bmngrd: 2	er: 0	her2 status: N	her2 fish: 1.04	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505527/suppl/GSM505527_FL749-425.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	60	2	N	0	1.04	NA	N	IDC	1	RD	N	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505528	BR_FNA_M430	GSM505528	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 430, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 fish: 1.01	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505528/suppl/GSM505528_FL499-430.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	52	3	N	0	1.01	NA	N	IDC	1	RD	N	black	3	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505529	BR_FNA_M431	GSM505529	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 431, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 25	her2 status: N	her2 ihc: 1	her2 fish: 0.94	histology: IDC/ILC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505529/suppl/GSM505529_FL557-431.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	2	P	25	0.94	1	N	IDC/ILC	1	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505530	BR_FNA_M433	GSM505530	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 433, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 70	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFEC	treatments comments: Taxol x12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505530/suppl/GSM505530_FL575-433.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	3	P	70	NA	0	N	IDC	0	RD	P	hispanic	2	breast cancer cells	TFEC	Taxol x12 FEC x 4
GSM505531	BR_FNA_M443	GSM505531	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 443, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 2	bmngrd: 3	er: 0	her2 status: P	her2 ihc: 3	her2 fish: 6	histology: IDC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505531/suppl/GSM505531_U133A_80-FL-095_FL271-443_05_11_06.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	46	3	N	0	6	3	P	IDC	2	pCR	N	white	3	breast cancer cells	NA	Taxol x 12 FEC x 4
GSM505532	BR_FNA_M486	GSM505532	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 486, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 80	her2 status: N	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505532/suppl/GSM505532_FL750-486.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	44	3	P	80	NA	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505533	BR_FNA_M502	GSM505533	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 502, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 0	her2 status: N	her2 fish: 1.6	histology: IDC/ILC	treatment code: FECT	treatments comments: FEC x 3 (N.C) Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505533/suppl/GSM505533_FL686-502.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	50	2	N	0	1.6	NA	N	IDC/ILC	0	RD	N	white	2	breast cancer cells	FECT	FEC x 3 (N.C) Taxol x 12
GSM505534	BR_FNA_M507	GSM505534	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 507, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 66	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 95	her2 status: N	her2 ihc: 1	her2 fish: 0.91	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505534/suppl/GSM505534_FL646-507.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	66	2	P	95	0.91	1	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505535	BR_FNA_M513	GSM505535	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 513, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 0.96	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4(d/t N.C) Taxol x 6 (d/t severe Fatigue) (FAC resistance & pCR at the end)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505535/suppl/GSM505535_FL491-513.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	59	3	N	0	0.96	1	N	IDC	1	pCR	N	black	2	breast cancer cells	TFAC	FAC x 4(d/t N.C) Taxol x 6 (d/t severe Fatigue) (FAC resistance & pCR at the end)
GSM505536	BR_FNA_M531	GSM505536	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 531, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 1.2	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505536/suppl/GSM505536_FL500-531.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	3	N	0	1.2	1	N	IDC	3	RD	N	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505537	BR_FNA_M545	GSM505537	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 545, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: black	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.08	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505537/suppl/GSM505537_FL501-545.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	58	3	N	0	1.08	2	N	IDC	1	RD	N	black	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505538	BR_FNA_M549	GSM505538	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 549, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 fish: 1.17	histology: IDC/ILC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505538/suppl/GSM505538_FL796-549.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	40	2	P	100	1.17	NA	N	IDC/ILC	1	RD	P	hispanic	2	breast cancer cells	TFEC	Taxol x 12 FEC x4
GSM505539	BR_FNA_M556	GSM505539	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 556, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1.06	histology: IDC/ILC	treatment code: TFAC/HT	treatments comments: Taxol x 13 FAC x 3(d/t cardiotox)   Anastrozole  x 3 Moths	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505539/suppl/GSM505539_FL457-556.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	90	1.06	1	N	IDC/ILC	1	RD	P	white	1	breast cancer cells	TFAC/HT	Taxol x 13 FAC x 3(d/t cardiotox)   Anastrozole  x 3 Moths
GSM505540	BR_FNA_M557	GSM505540	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 557, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 57	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 1	her2 status: N	her2 fish: 1.17	histology: IDC	treatment code: TFAC	treatments comments: Taxol x12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505540/suppl/GSM505540_FL597-557.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	57	3	N	1	1.17	NA	N	IDC	3	pCR	N	white	2	breast cancer cells	TFAC	Taxol x12 FAC x 4
GSM505541	BR_FNA_M558	GSM505541	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 558, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505541/suppl/GSM505541_FL752-558.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	62	3	N	0	NA	0	N	IDC	3	RD	N	white	4	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505542	BR_FNA_M559	GSM505542	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 559, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 55	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 70	her2 status: N	her2 fish: 1.14	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505542/suppl/GSM505542_FL598-559.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	55	2	P	70	1.14	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505543	BR_FNA_M564	GSM505543	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 564, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 68	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505543/suppl/GSM505543_FL599-564.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	68	3	N	0	NA	0	N	IDC	2	RD	N	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505544	BR_FNA_M566	GSM505544	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 566, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 39	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 2	er: 90	her2 status: N	her2 fish: 1.22	histology: IDC	treatment code: TFAC	treatments comments: Taxol x  12  FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505544/suppl/GSM505544_FL600-566.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	39	2	P	90	1.22	NA	N	IDC	3	RD	N	white	2	breast cancer cells	TFAC	Taxol x  12  FAC x 4
GSM505545	BR_FNA_M571	GSM505545	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 571, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 32	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: FACT	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505545/suppl/GSM505545_U133A_80-FL-206-FL370-571_08_25_06.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	32	3	N	0	NA	0	N	IDC	1	pCR	N	black	2	breast cancer cells	FACT	FAC x 4 Taxol x 12
GSM505546	BR_FNA_M576	GSM505546	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 576, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 70	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: P	her2 fish: 7.25	histology: IDC	treatments comments: Taxol x 12 FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505546/suppl/GSM505546_U133A_80-FL-110_FL286-576_05_22_06.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	70	3	N	0	7.25	NA	P	IDC	1	RD	N	white	2	breast cancer cells	NA	Taxol x 12 FAC x 4
GSM505547	BR_FNA_M578	GSM505547	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 578, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 1	bmngrd: 3	er: 100	her2 status: N	her2 ihc: 2	her2 fish: 1.55	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505547/suppl/GSM505547_FL502-578.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	3	P	100	1.55	2	N	IDC	1	RD	P	black	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505548	BR_FNA_M583	GSM505548	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 583, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 0	her2 fish: 0.97	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12  FAC x 6	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505548/suppl/GSM505548_FL503-583.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	51	2	N	0	0.97	0	N	IDC	3	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12  FAC x 6
GSM505549	BR_FNA_M599	GSM505549	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 599, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 1	bmngrd: 1	er: 80	her2 status: N	her2 ihc: 2	her2 fish: 1.47	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12  FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505549/suppl/GSM505549_FL557-599.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	1	P	80	1.47	2	N	IDC	1	RD	P	white	1	breast cancer cells	TFEC	Taxol x 12  FEC x 4
GSM505550	BR_FNA_M607	GSM505550	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 607, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 67	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 1	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 fish: 1.21	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505550/suppl/GSM505550_FL647-607-2.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	67	2	P	90	1.21	NA	N	IDC	1	RD	N	white	1	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505551	BR_FNA_M610	GSM505551	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 610, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 2	bmngrd: 2	er: 80	her2 status: N	her2 ihc: 1	her2 fish: 1.32	histology: IDC/LDC	treatment code: TFAC	treatments comments: Taxol x 12  FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505551/suppl/GSM505551_FL602-610.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	80	1.32	1	N	IDC/LDC	2	RD	P	hispanic	3	breast cancer cells	TFAC	Taxol x 12  FAC x 4
GSM505552	BR_FNA_M612	GSM505552	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 612, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 2	bmngrd: 3	er: 1	her2 status: N	her2 fish: 1.23	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12   FAC x 2  ( d/t CVC infection )	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505552/suppl/GSM505552_FL690-612.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	40	3	N	1	1.23	NA	N	IDC	2	RD	N	white	2	breast cancer cells	TFAC	Taxol x 12   FAC x 2  ( d/t CVC infection )
GSM505553	BR_FNA_M617	GSM505553	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 617, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 fish: 1.2	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12  FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505553/suppl/GSM505553_U133A_80-FL-131-FL299-617_06_09_06.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	50	3	N	0	1.2	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFEC	Taxol x 12  FEC x 4
GSM505554	BR_FNA_M619	GSM505554	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 619, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 fish: 1.05	histology: IDC	treatment code: FACT+XRT/X	treatments comments: FAC x 6 Taxol  x 12 /  XRT+ Xeloda (as a neo-adj setting)	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505554/suppl/GSM505554_FL678-619.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	52	3	N	0	1.05	NA	N	IDC	2	RD	N	white	4	breast cancer cells	FACT+XRT/X	FAC x 6 Taxol  x 12 /  XRT+ Xeloda (as a neo-adj setting)
GSM505555	BR_FNA_M626	GSM505555	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 626, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	her2 status: P	her2 ihc: 3	her2 fish: 1.1	histology: IDC	treatments comments: Taxol x 12  FEC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505555/suppl/GSM505555_FL755-626.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	3	N	NA	1.1	3	P	IDC	1	RD	N	hispanic	2	breast cancer cells	NA	Taxol x 12  FEC x 4
GSM505556	BR_FNA_M642	GSM505556	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 642, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 2	bmngrd: 2	er: 95	her2 status: N	her2 fish: 1.09	histology: IDC	treatment code: TFEC	treatments comments: FEC x 4  Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505556/suppl/GSM505556_FL786_642.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	2	P	95	1.09	NA	N	IDC	2	RD	P	hispanic	4	breast cancer cells	TFEC	FEC x 4  Taxol x 12
GSM505557	BR_FNA_M643	GSM505557	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 643, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 41	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 1	her2 fish: 1.08	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505557/suppl/GSM505557_FL797-643.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	41	2	P	90	1.08	1	N	IDC	0	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505558	BR_FNA_M647	GSM505558	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 647, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 65	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 0.93	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505558/suppl/GSM505558_FL688-647.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	65	3	N	0	0.93	2	N	IDC	1	RD	N	white	3	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505559	BR_FNA_M651	GSM505559	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 651, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 61	race: white	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 3	er: 90	her2 status: N	her2 fish: 1.3	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 9 (d/t severe parestesias)    FACx 2 (d/t Cholecystiitis + Sx)	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505559/suppl/GSM505559_FL604-651.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	61	3	P	90	1.3	NA	N	IDC	1	pCR	P	white	2	breast cancer cells	TFAC	Taxol x 9 (d/t severe parestesias)    FACx 2 (d/t Cholecystiitis + Sx)
GSM505560	BR_FNA_M652	GSM505560	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 652, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 66	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 20	her2 status: N	her2 ihc: 0	histology: IDC/ILC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x12 (Abraxene)	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505560/suppl/GSM505560_FL605-652.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	66	2	P	20	NA	0	N	IDC/ILC	1	RD	N	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x12 (Abraxene)
GSM505561	BR_FNA_M657	GSM505561	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 657, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 48	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 0	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 0.96	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505561/suppl/GSM505561_FL756-657.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	48	2	N	0	0.96	1	N	IDC	0	RD	P	hispanic	1	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505562	BR_FNA_M658	GSM505562	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 658, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 61	race: hispanic	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 3	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12   FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505562/suppl/GSM505562_FL606-658.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	61	3	N	0	NA	0	N	IDC	3	pCR	N	hispanic	3	breast cancer cells	TFAC	Taxol x 12   FAC x 4
GSM505563	BR_FNA_M659	GSM505563	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 659, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: asian	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 1	her2 fish: 1.05	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 10 (D/T  N.C swith to) FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505563/suppl/GSM505563_FL827-659.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	51	3	N	0	1.05	1	N	IDC	1	RD	N	asian	2	breast cancer cells	TFAC	Taxol x 10 (D/T  N.C swith to) FAC x 4
GSM505564	BR_FNA_M661	GSM505564	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 661, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 0.79	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 2 (D/T severe allergic reaction)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505564/suppl/GSM505564_FL679-661.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	49	3	N	0	0.79	2	N	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 2 (D/T severe allergic reaction)
GSM505565	BR_FNA_M662	GSM505565	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 662, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 0.89	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505565/suppl/GSM505565_FL577-662.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	2	P	90	0.89	0	N	IDC	1	RD	P	asian	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505566	BR_FNA_M665	GSM505566	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 665, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 57	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505566/suppl/GSM505566_FL780-665.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	57	3	N	0	NA	0	N	IDC	1	pCR	N	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505567	BR_FNA_M666	GSM505567	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 666, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 fish: 0.91	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505567/suppl/GSM505567_FL559-666.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	58	2	P	100	0.91	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505568	BR_FNA_M668	GSM505568	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 668, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 2	bmngrd: 3	er: 80	her2 status: N	her2 fish: 2	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505568/suppl/GSM505568_FL680-668.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	50	3	P	80	2	NA	N	IDC	2	RD	P	asian	3	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505569	BR_FNA_M669	GSM505569	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 669, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 2	her2 fish: 0.86	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505569/suppl/GSM505569_FL578-669.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	90	0.86	2	N	IDC	1	RD	P	asian	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505570	BR_FNA_M670	GSM505570	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 670, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 43	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 0	her2 status: N	her2 fish: 1.06	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505570/suppl/GSM505570_FL781-670.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	43	2	N	0	1.06	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505571	BR_FNA_M671	GSM505571	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 671, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 30	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 1	nbefore: 1	bmngrd: 3	er: 90	her2 status: N	her2 fish: 1.07	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505571/suppl/GSM505571_FL560-671.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	30	3	P	90	1.07	NA	N	IDC	1	RD	P	white	1	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505572	BR_FNA_M673	GSM505572	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 673, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 11 ( one dose missed & no repleced) FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505572/suppl/GSM505572_FL689-673.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	58	3	N	0	NA	0	N	IDC	3	RD	N	white	2	breast cancer cells	TFEC	Taxol x 11 ( one dose missed & no repleced) FEC x 4
GSM505573	BR_FNA_M675	GSM505573	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 675, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 1	her2 status: N	her2 ihc: 1	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505573/suppl/GSM505573_FL579-675.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	64	2	N	1	NA	1	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x4
GSM505574	BR_FNA_M679	GSM505574	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 679, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 72	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.42	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505574/suppl/GSM505574_FL580-679.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	72	3	N	0	1.42	2	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505575	BR_FNA_M681	GSM505575	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 681, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 33	race: hispanic	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 3	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.27	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505575/suppl/GSM505575_FL783-681.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	33	3	N	0	1.27	2	N	IDC	0	RD	N	hispanic	3	breast cancer cells	TFEC	Taxol x 12 FEC x4
GSM505576	BR_FNA_M682	GSM505576	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 682, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	her2 status: N	her2 ihc: 2	her2 fish: 1.2	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 10 (D/T severe low ANC) FEC x4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505576/suppl/GSM505576_FL761-682.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	50	2	P	NA	1.2	2	N	IDC	0	RD	P	white	2	breast cancer cells	TFEC	Taxol x 10 (D/T severe low ANC) FEC x4
GSM505577	BR_FNA_M683	GSM505577	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 683, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 59	race: white	er_status: N	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 3	er: 5	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505577/suppl/GSM505577_FL581-683.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	59	3	N	5	NA	0	N	IDC	0	RD	P	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x4
GSM505578	BR_FNA_M685	GSM505578	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 685, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 1	er: 90	her2 status: N	her2 fish: 0	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12  FEC x4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505578/suppl/GSM505578_FL787-685.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	1	P	90	0	NA	N	IDC	0	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12  FEC x4
GSM505579	BR_FNA_M690	GSM505579	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 690, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 73	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 1	er: 95	her2 status: N	her2 ihc: 1	her2 fish: 0.86	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505579/suppl/GSM505579_FL561-690.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	73	1	P	95	0.86	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x4
GSM505580	BR_FNA_M692	GSM505580	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 692, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 2	er: 0	her2 status: N	her2 ihc: 1	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x  4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505580/suppl/GSM505580_FL582-692.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	46	2	N	0	NA	1	N	IDC	3	pCR	N	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x  4
GSM505581	BR_FNA_M693	GSM505581	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 693, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 47	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 fish: 0.82	histology: IDC/ILC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505581/suppl/GSM505581_FL562-693.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	47	2	P	90	0.82	NA	N	IDC/ILC	0	RD	P	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x12
GSM505582	BR_FNA_M695	GSM505582	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 695, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 43	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 80	her2 status: N	her2 fish: 1.21	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505582/suppl/GSM505582_FL648-695.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	43	3	P	80	1.21	NA	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505583	BR_FNA_M696	GSM505583	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 696, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: black	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 0.98	histology: IDC	treatment code: TFAC	treatments comments: Taxol x12 FAC x4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505583/suppl/GSM505583_FL607-696.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	53	3	N	0	0.98	2	N	IDC	1	pCR	N	black	2	breast cancer cells	TFAC	Taxol x12 FAC x4
GSM505584	BR_FNA_M709	GSM505584	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 709, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: N	pcr_vs_rd: pCR	pr_status: N	tbefore: 4	nbefore: 2	bmngrd: 3	her2 status: N	her2 fish: 1.9	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505584/suppl/GSM505584_FL608-709.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	51	3	N	NA	1.9	NA	N	IDC	2	pCR	N	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505585	BR_FNA_M710	GSM505585	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 710, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 100	her2 status: N	her2 ihc: 0	histology: ILC/IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505585/suppl/GSM505585_FL682-710.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	2	P	100	NA	0	N	ILC/IDC	1	RD	P	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505586	BR_FNA_M714	GSM505586	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 714, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 3	er: 30	her2 status: N	her2 fish: 0.96	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 4 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505586/suppl/GSM505586_FL788-714.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	64	3	P	30	0.96	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFEC	Taxol x 4 FEC x 4
GSM505587	BR_FNA_M717	GSM505587	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 717, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 52	race: asian	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 1	er: 100	her2 status: N	her2 fish: 0.94	histology: IDC	treatment code: TFEC	treatments comments: FEC x 5 (d/t NC) switch to Taxol x 10 (Pt missed two doses)	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505587/suppl/GSM505587_FL609-717.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	52	1	P	100	0.94	NA	N	IDC	0	RD	P	asian	2	breast cancer cells	TFEC	FEC x 5 (d/t NC) switch to Taxol x 10 (Pt missed two doses)
GSM505588	BR_FNA_M718	GSM505588	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 718, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 36	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 2	her2 fish: 1.32	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505588/suppl/GSM505588_FL610-718.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	36	3	N	0	1.32	2	N	IDC	0	RD	N	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505589	BR_FNA_M723	GSM505589	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 723, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 63	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 95	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505589/suppl/GSM505589_FL564-723.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	63	2	P	95	NA	0	N	IDC	1	RD	P	hispanic	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505590	BR_FNA_M725	GSM505590	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 725, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 46	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 3	bmngrd: 1	er: 91	her2 status: N	her2 ihc: 1	her2 fish: 1.25	histology: IDC	treatment code: FECT	treatments comments: FEC x 6 (P.D “new supra & infraclavicular Ln”)Taxol x 12	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505590/suppl/GSM505590_FL683-725.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	46	1	P	91	1.25	1	N	IDC	3	RD	P	white	2	breast cancer cells	FECT	FEC x 6 (P.D “new supra & infraclavicular Ln”)Taxol x 12
GSM505591	BR_FNA_M728	GSM505591	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 728, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 1	bmngrd: 3	er: 100	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFAC	treatments comments: FAC x 4 Taxol x 12	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505591/suppl/GSM505591_FL611-728.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	49	3	P	100	NA	0	N	IDC	1	RD	P	black	3	breast cancer cells	TFAC	FAC x 4 Taxol x 12
GSM505592	BR_FNA_M732	GSM505592	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 732, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 50	race: white	er_status: N	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 2	bmngrd: 3	er: 0	her2 status: N	her2 ihc: 0	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505592/suppl/GSM505592_FL612-732.CEL.gz	22283	Reanalyzed by: GSE31519	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	50	3	N	0	NA	0	N	IDC	2	RD	N	white	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505593	BR_FNA_M734	GSM505593	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 734, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 36	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 fish: 1.18	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505593/suppl/GSM505593_FL789-734.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	36	2	P	90	1.18	NA	N	IDC	0	RD	P	black	2	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505594	BR_FNA_M744	GSM505594	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 744, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 44	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 95	her2 status: N	her2 fish: 0.87	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505594/suppl/GSM505594_FL614-744.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	44	2	P	95	0.87	NA	N	IDC	1	RD	N	white	2	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505595	BR_FNA_M746	GSM505595	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 746, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 56	race: black	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 1	er: 10	her2 status: N	her2 ihc: 0	histology: ILC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505595/suppl/GSM505595_FL685-746.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	56	1	P	10	NA	0	N	ILC	0	RD	P	black	3	breast cancer cells	TFEC	Taxol x 12 FEC x 4
GSM505596	BR_FNA_M753	GSM505596	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 753, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 2	er: 100	her2 status: N	her2 fish: 1.18	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505596/suppl/GSM505596_FL701-753.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	49	2	P	100	1.18	NA	N	IDC	0	RD	P	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x 4
GSM505597	BR_FNA_M765	GSM505597	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 765, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 62	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 1	bmngrd: 3	er: 95	her2 status: N	her2 fish: 0.93	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12  FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505597/suppl/GSM505597_FL681-765.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	62	3	P	95	0.93	NA	N	IDC	1	RD	P	white	4	breast cancer cells	TFAC	Taxol x 12  FAC x 4
GSM505598	BR_FNA_M767	GSM505598	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 767, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 51	race: white	er_status: P	pcr_vs_rd: pCR	pr_status: P	tbefore: 2	nbefore: 0	bmngrd: 2	er: 91	her2 status: N	her2 ihc: 1	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12  FAC x 4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505598/suppl/GSM505598_FL670-767.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	51	2	P	91	NA	1	N	IDC	0	pCR	P	white	2	breast cancer cells	TFAC	Taxol x 12  FAC x 4
GSM505599	BR_FNA_M774	GSM505599	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 774, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 2	nbefore: 1	bmngrd: 2	er: 95	her2 status: N	her2 ihc: 1	her2 fish: 0.83	histology: IDC	treatment code: TFEC	treatments comments: Taxol x   12 FEC x  4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505599/suppl/GSM505599_FL658-774.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	49	2	P	95	0.83	1	N	IDC	1	RD	P	white	2	breast cancer cells	TFEC	Taxol x   12 FEC x  4
GSM505600	BR_FNA_M781	GSM505600	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 781, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 40	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 3	nbefore: 0	bmngrd: 2	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 1.17	histology: IDC	treatment code: TFEC	treatments comments: Taxol x 12 FEC x  4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505600/suppl/GSM505600_FL660-781.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	40	2	P	90	1.17	0	N	IDC	0	RD	P	white	3	breast cancer cells	TFEC	Taxol x 12 FEC x  4
GSM505601	BR_FNA_M782	GSM505601	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 782, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 53	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 3	bmngrd: 1	er: 90	her2 status: N	her2 ihc: 0	her2 fish: 0.54	histology: ILC	treatment code: TFAC	treatments comments: Tamoxifen x 2 weeks  Taxol x 12 FAC x 4	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505601/suppl/GSM505601_FL703-782.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	53	1	P	90	0.54	0	N	ILC	3	RD	N	white	2	breast cancer cells	TFAC	Tamoxifen x 2 weeks  Taxol x 12 FAC x 4
GSM505602	BR_FNA_M784	GSM505602	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 784, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 58	race: white	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 0	bmngrd: 3	er: 100	her2 status: N	her2 fish: 1.29	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 12 FAC x  6	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505602/suppl/GSM505602_FL704-784.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	58	3	P	100	1.29	NA	N	IDC	0	RD	P	white	4	breast cancer cells	TFAC	Taxol x 12 FAC x  6
GSM505603	BR_FNA_M795	GSM505603	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 795, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 64	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 0	bmngrd: 2	er: 85	her2 status: N	her2 fish: 0.86	histology: IDC	treatment code: TFAC	treatments comments: Taxol x  12 FAC x  4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505603/suppl/GSM505603_FL799-795.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	64	2	P	85	0.86	NA	N	IDC	0	RD	N	white	2	breast cancer cells	TFAC	Taxol x  12 FAC x  4
GSM505604	BR_FNA_M801	GSM505604	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 801, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 45	race: white	er_status: P	pcr_vs_rd: RD	pr_status: N	tbefore: 2	nbefore: 1	bmngrd: 2	er: 91	her2 status: N	her2 ihc: 1	histology: IDC	treatment code: TFEC	treatments comments: Taxol x  12 FEC x  4	NA	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505604/suppl/GSM505604_FL1141-801_2_.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	45	2	P	91	NA	1	N	IDC	1	RD	N	white	2	breast cancer cells	TFEC	Taxol x  12 FEC x  4
GSM505605	BR_FNA_M806	GSM505605	Public on Feb 04 2010	Feb 02 2010	Jun 06 2022	RNA	1	Sample ID -- 806, fine-needle aspiration, breast cancer cells	Homo sapiens	tissue: breast cancer cells	age: 49	race: hispanic	er_status: P	pcr_vs_rd: RD	pr_status: P	tbefore: 4	nbefore: 2	bmngrd: 3	er: 100	her2 status: N	her2 ihc: 1	her2 fish: 1.16	histology: IDC	treatment code: TFAC	treatments comments: Taxol x 8 ( d/t NC) FAC x 3 (d/t PD) Xeloda (1) Letrozole + Gleevec (PD) +XRT (rt breast, bi-supra and IMC w/ xeloda)	Patients received pretreatment fine-needle aspiration (FNA) of the primary breast tumor or ipsilateral axillary metastasis before starting chemotherapy as part of an ongoing pharmacogenomic marker discovery program. The aspiration was performed using a 23- or 25-gauge needle. Cells from two to three passes were collected in vials containing 1 mL RNA later solution (Ambion, Austin, TX) and stored at -80°C. FNA samples on average contain 80% neoplastic cells and contain little or no stromal cells or normal breast epithelium.	total RNA	RNA was extracted from FNA samples using the RNAeasy Kit (Qiagen, Valencia, CA). The amount and quality of RNA were assessed with DU-640 UV Spectrophotometer (Beckman Coulter, Fullerton, CA), and they were considered adequate for further analysis if the optical density 260/280 ratio was ≥1.8 and the total RNA yield was ≥ 1μg.	biotin	biotin labeling	9606	Affymetrix protocol	Affymetrix protocol	MAQC_Distribution_Status: MAQC_V -- Validation	Please see the GSE20194_MDACC_Sample_Info.xls file on the GSE20194 Series record for additional information on the Sample characteristics	MAS5	GPL96	Leming,,Shi	lemingshi@fudan.edu.cn	+86-18616827008	Center for Pharmacogenomics	School of Life Sciences	Fudan University	2005 Songhu Road	Shanghai	200438	China	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM505nnn/GSM505605/suppl/GSM505605_FL802-806.CEL.gz	22283	Reanalyzed by: GSE47561	Reanalyzed by: GSE205568	NA	49	3	P	100	1.16	1	N	IDC	2	RD	P	hispanic	4	breast cancer cells	TFAC	Taxol x 8 ( d/t NC) FAC x 3 (d/t PD) Xeloda (1) Letrozole + Gleevec (PD) +XRT (rt breast, bi-supra and IMC w/ xeloda)
